Table 4.

Outcome during HCQ therapy

	Overall (n = 649)	HT (n = 126)	MW (n = 495)	ICU (n = 28)
Follow up time (days), median [IQR]	16 (9–20]	15 [8–20]	16 (9–210	19 (6–23)
HCQ suspension due to QT prolongation, n (%)	5 (0.8)	0	2 (0.4)	3 (10.7)
Sustained VT during HCQ, n (%)	4 (0.6)	0	2 (0.4)	2 (7.1)
VF during HCQ, n (%)	3 (0.5)	0	0	3 (10.7)
TdP during HCQ, n (%)	0	0	0	0
AF/AFl episodes, n (%)	15 (2.3)	2 (1.6)	6 (1.2)	7 (25.0)
Bradycardia episodes, n (%)	9 (1.4)	0	4 (0.8)	5 (17.8)
Overall mortality, n (%)	42 (6.5)	2 (1.6)	30 (6.1)	10 (35.7)

AF, atrial fibrillation; AFl, atrial flutter; HCQ, hydroxychloroquine; VT, ventricular tachycardia.